|
Mutation Information
|
Mutation Site
|
T184L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Viral Reference
|
X75665.1
|
|
Relevant Drug
|
lamivudine (LAM);entecavir (ETV) |
|
Country
|
Japan;United States; Hong Kong |
Literature Information
|
PubMed PMID
|
19933798
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2010 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. |
|
Author
|
Mukaide M,Tanaka Y,Shin-I T,Yuen MF,Kurbanov F,Yokosuka O,Sata M,Karino Y,Yamada G,Sakaguchi K,Orito E,Inoue M,Baqai S,Lai CL,Mizokami M |
|
Evidence
|
Modeling of HBV reverse transcriptase (RT) by docking simulation indicated that a combination of LVDr and ETVr (T184L or S202G) was characterized by a change in the direction of the D205 residue and steric conflict in the binding pocket of ETV triphosphate (ETV-TP), by significantly longer minimal distances (2.
|
|
|
HBV Mutation Detail Information